fig2
![Longitudinal biomarker evaluation in Fabry disease patients receiving lentivirus-mediated gene therapy](https://image.oaes.cc/2756c62d-7277-4d07-8ccb-b6ea7b2d1282/rdodj4014.fig.2.jpg)
Figure 2. Urine and plasma specimen collection time points according to the types of treatment for 5 Fabry patients who received gene therapy.
Figure 2. Urine and plasma specimen collection time points according to the types of treatment for 5 Fabry patients who received gene therapy.
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/